U.S. markets open in 2 hours 21 minutes

Wired News – Synlogic Announced First Subject Dosed in Phase-1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis

Stock Monitor: Ascendis Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 04, 2018 / Active-Investors.com has just released a free research report on Synlogic, Inc. (NASDAQ: SYBX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SYBX as the Company's latest news hit the wire. On April 02, 2018, the Company announced that the first patient was dosed in its Phase-1b/2a clinical study evaluating the safety and tolerability of SYNB1020, a novel, first-in-class, Synthetic Biotic medicine being developed for the treatment of hyperammonemia, associated with cirrhosis and urea cycle disorders (UCDs). Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for Ascendis Pharma A/S (NASDAQ: ASND), which also belongs to the Healthcare sector as the Company Synlogic. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Synlogic most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


The Company is likely to report top-line data from this trial by year-end 2018.

Synlogic is Evaluating SYNB1020 in Liver Disease Patients with Cirrhosis

Aoife Brennan, M.B., B.Ch., Chief Medical Officer at Synlogic, stated that the Company's recently reported Phase-1 trial of SYNB1020 demonstrated that this Synthetic Biotic medicine was well tolerated and provided a dose-dependent proof of mechanism, functioning as designed in healthy volunteers.

According to M. Brennan, Synlogic looks forward to evaluating the safety, tolerability, and therapeutic potential of SYNB1020 in patients with liver disease who have developed cirrhosis.

Synlogic Reported Positive Top-line Phase-1 Data for SYNB1020 for Treatment of Hyperammonemia

In November 2017, the Company announced positive top-line clinical data from its Phase-1 placebo-controlled single (SAD) and multiple ascending dose (MAD) clinical trial of SYNB1020 in healthy volunteers. The trial successfully met the primary objectives demonstrating safety and tolerability in healthy volunteers and identifying the maximum tolerated dose. Furthermore, proof of mechanism was demonstrated by a clear signal in a plasma nitrogen endpoint. These data supported the hypothesis that SYNB1020 treatment might provide clinical benefit in patients with UCDs or liver disease.

About Phase-1b/2a Trial of SYNB1020 in Patients with Cirrhosis

This Phase-1b/2a study has two parts:

First, an initial sentinel open-label cohort of subjects with cirrhosis and a MELD score < 12 will receive orally administered SYNB1020 for six days. Once safety and tolerability have been established in subjects, enrollment will be opened to subjects in Part 2;

Part 2 of the trial comprises a randomized, double-blinded, placebo-controlled study in patients with cirrhosis and hyperammonemia. Eligible subjects with an elevated ammonia level will proceed with randomization and receive either placebo or orally administered SYNB1020 for six days. The primary endpoint of the study is safety and tolerability. In addition, the study will evaluate the effect of SYNB1020 administration on plasma ammonia levels as well as other exploratory endpoints.

About Hyperammonemia

Hyperammonemia is a metabolic disturbance characterized by an excess of ammonia in the blood. It is a dangerous condition that may lead to brain injury and death. Increased entry of ammonia to the brain is a primary cause of neurologic disorders, such as congenital deficiencies of urea cycle enzymes, hepatic encephalopathies, Reye syndrome, and several other metabolic disorders. In healthy individuals, ammonia is primarily produced in the intestine as a byproduct of protein metabolism and microbial degradation of nitrogen-containing compounds. Ammonia is then converted to urea in the liver and is excreted in urine. However, if the liver's ability to convert ammonia to urea is compromised, either due to a genetic defect such as UCDs or acquired liver disease that leads to cirrhosis, ammonia accumulates in the blood.

About SYNB1020

SYNB1020 is a Synthetic Biotic medicine designed to remove excess ammonia from the blood. SYNB1020 operates from the gut microbiome and is engineered to activate a programmed metabolic pathway to remove excess ammonia for the treatment of UCD and other forms of hyperammonemia. By performing these metabolic activities, SYNB1020 may reduce abnormal levels of ammonia in the blood, compensating for defects in the intrinsic urea cycle.

In June 2016, Synlogic was granted Fast Track Designation from the US Food and Drug Administration (FDA) for SYNB1020 for the treatment of hyperammonemia in a group of UCDs.

About Synlogic, Inc.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Synlogic is dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. The Company is pioneering the development of a novel class of living Synthetic Biotic medicines based on its proprietary drug discovery and development platform.

Stock Performance Snapshot

April 03, 2018 - At Tuesday's closing bell, Synlogic's stock dropped 2.21%, ending the trading session at $9.29.

Volume traded for the day: 43.39 thousand shares.

After yesterday's close, Synlogic's market cap was at $200.85 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.3% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors